Related Experiment Video
Updated: Mar 13, 2026
Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors
Published on: December 16, 2022
Correlation between anti-PD-L1 tumor concentrations and tumor-specific and nonspecific biomarkers in a melanoma mouse
Ana M Contreras-Sandoval1, María Merino1, Marcos Vasquez2
1School of Pharmacy, Department of Pharmacy and Pharmaceutical Technology, University of Navarra, 31008 Pamplona, Spain.
Abstract:
Blockade of PD-L1 with specific monoclonal antibodies (anti-PD-L1) represents a therapeutic strategy to increase the capability of the immune system to modulate the tumor immune-resistance. The relationship between anti-PD-L1 tumor exposition and anti-tumor effect represents a challenge that has been addressed in this work through the identification of certain biomarkers implicated in the antibody's mechanism of action, using a syngeneic melanoma mouse model. The development of an in-vitro/in-vivo platform has allowed us to investigate the PD-L1 behavior after its blockage with anti-PD-L1 at cellular level and in animals. In-vitro studies showed that the complex PD-L1/anti-PD-L1 was retained mainly at the cell surface. The antibody concentration and time exposure affected directly the recycling or ligand turnover. In-vivo studies showed that anti-PD-L1 was therapeutically active at all stage of the disease, with a rapid onset, a low but durable efficacy and non-relevant toxic effect. This efficacy measured as tumor shrinkage correlated with tumor-specific infiltrating lymphocytes (TILs), which increased as antibody tumor concentrations increased. Both, TILS and antibody concentrations followed similar kinetic patterns, justifying the observed anti-PD-L1 rapid onset. Interestingly, peripheral lymphocytes (PBLs) behave as infiltrating lymphocytes, suggesting that these PBLs might be considered as a possible biomarker for antibody activity.
Insights
Blockade of programmed death-ligand 1 (PD-L1) with antibodies enhances anti-tumor immunity. This study identified biomarkers, including peripheral lymphocytes, correlating with PD-L1 blockade efficacy in a melanoma mouse model.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- Programmed death-ligand 1 (PD-L1) blockade using monoclonal antibodies (anti-PD-L1) is a strategy to enhance anti-tumor immune responses.
- Understanding the relationship between anti-PD-L1 exposure and therapeutic effect is crucial for optimizing cancer immunotherapy.
Purpose of the Study:
- To identify biomarkers associated with the mechanism of action of anti-PD-L1 therapy.
- To investigate PD-L1 behavior and anti-tumor effects following PD-L1 blockade in a syngeneic melanoma mouse model.
Main Methods:
- Development of an in-vitro/in-vivo platform to study PD-L1 dynamics and anti-PD-L1 efficacy.
- Analysis of antibody-target complex localization and turnover at the cellular level.
- Assessment of therapeutic activity, tumor shrinkage, and immune cell infiltration in vivo.
Main Results:
- In vitro, the PD-L1/anti-PD-L1 complex was primarily retained on the cell surface, with recycling/turnover influenced by antibody concentration and exposure time.
- In vivo, anti-PD-L1 demonstrated rapid onset, durable efficacy with minimal toxicity across disease stages.
- Therapeutic efficacy correlated with increased tumor-specific infiltrating lymphocytes (TILs) and antibody concentration, with similar kinetic patterns observed.
Conclusions:
- Peripheral lymphocytes (PBLs) mirrored the behavior of infiltrating lymphocytes, suggesting their potential as biomarkers for anti-PD-L1 activity.
- The study provides insights into the pharmacodynamics and efficacy of PD-L1 blockade, highlighting TILs and PBLs as key indicators.
